ATE234099T1 - Immununterdrückende effekte von 8 substituierten xanthinderivaten - Google Patents

Immununterdrückende effekte von 8 substituierten xanthinderivaten

Info

Publication number
ATE234099T1
ATE234099T1 AT98201323T AT98201323T ATE234099T1 AT E234099 T1 ATE234099 T1 AT E234099T1 AT 98201323 T AT98201323 T AT 98201323T AT 98201323 T AT98201323 T AT 98201323T AT E234099 T1 ATE234099 T1 AT E234099T1
Authority
AT
Austria
Prior art keywords
substituted
carbon atoms
unsubstituted
phenyl
group
Prior art date
Application number
AT98201323T
Other languages
English (en)
Inventor
Mark Jozef Albert Waer
Piet Andre Maurits M Herdewijn
Wolfgang Pfleiderer
Original Assignee
Leuven K U Res & Dev
Wolfgang Pfleiderer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven K U Res & Dev, Wolfgang Pfleiderer filed Critical Leuven K U Res & Dev
Application granted granted Critical
Publication of ATE234099T1 publication Critical patent/ATE234099T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
AT98201323T 1998-04-24 1998-04-24 Immununterdrückende effekte von 8 substituierten xanthinderivaten ATE234099T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98201323A EP0956855B1 (de) 1998-04-24 1998-04-24 Immununterdrückende Effekte von 8 substituierten Xanthinderivaten

Publications (1)

Publication Number Publication Date
ATE234099T1 true ATE234099T1 (de) 2003-03-15

Family

ID=8233642

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98201323T ATE234099T1 (de) 1998-04-24 1998-04-24 Immununterdrückende effekte von 8 substituierten xanthinderivaten

Country Status (5)

Country Link
EP (1) EP0956855B1 (de)
AT (1) ATE234099T1 (de)
DE (1) DE69812070T2 (de)
DK (1) DK0956855T3 (de)
ES (1) ES2189079T3 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
CA2356380C (en) * 1998-12-28 2008-06-17 K.U. Leuven Research & Development Immunosuppressive effects of pteridine derivatives
KR100937620B1 (ko) 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
DK1622908T3 (da) * 2003-05-06 2008-11-17 Cv Therapeutics Inc Xanthin-derivater som A2B adenosin-receptor-antagonister
AU2011202523B2 (en) * 2003-11-21 2013-05-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
JP2010524970A (ja) 2007-04-20 2010-07-22 デシフェラ ファーマシューティカルズ，エルエルシー 骨髄増殖性疾患及びその他の増殖性疾患の治療に有用なキナーゼ阻害剤
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
BRPI0920765A2 (pt) 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN111233863B (zh) * 2014-10-09 2022-10-25 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
BR112017007194B1 (pt) 2014-10-09 2023-11-07 Guangdong Raynovent Biotech Co., Ltd Compostos de hidroxil purina e uso dos mesmos
ME02893B (de) 2015-03-04 2018-04-20 Gilead Sciences Inc Toll-like-rezeptormodulierende 4,6-diamino-pyrido[3,2-d]pyrimidin-verbindungen
EP3507276B1 (de) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll-like-rezeptor-modulator-verbindungen
EP3507288B1 (de) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidinderivate als toll-like-rezeptor modulatoren
CN110041330B (zh) * 2018-01-16 2020-08-11 新发药业有限公司 一种伊曲茶碱的环保制备方法
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN110922363A (zh) * 2019-12-28 2020-03-27 新华制药（寿光）有限公司 一种紫脲酸连续化生产工艺
CA3163051A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
WO1996036638A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use

Also Published As

Publication number Publication date
DK0956855T3 (da) 2003-07-14
EP0956855A1 (de) 1999-11-17
DE69812070T2 (de) 2003-12-11
DE69812070D1 (de) 2003-04-17
ES2189079T3 (es) 2003-07-01
EP0956855B1 (de) 2003-03-12

Similar Documents

Publication Publication Date Title
ATE234099T1 (de) Immununterdrückende effekte von 8 substituierten xanthinderivaten
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
ES2082805T3 (es) Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos.
ATE52498T1 (de) Amidderivate.
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
HUT54279A (en) Herbicidal and bioregulating compositions comprising salicyl-aldehyde and salicylic acid derivatives and their sulfur analogs, as well as process for producing the active ingredients
PT87063A (pt) Heterocyclic compounds and their preparation and use
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
FR2598709B1 (fr) Derives de l'acide quinoleinecarboxylique
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
BRPI0408675A (pt) derivados de talidomida solúveis em água
DK384485A (da) 1,6-naphthyridinderivater med kardilaterende virkning
KR890009862A (ko) N-치환 메르캅토 프로판아미드 유도체
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드
KR910000150A (ko) 대사성 골 질환 치료제
ATE222583T1 (de) Derivate substituierter amidinonaphthylester
KR910700236A (ko) 치환된 3-아자비사이클로[3,1,1]헵탄, 이의 제조방법 및 이의 용도
ATE135571T1 (de) Organogermaniumderivate enthaltende zubereitungen zur therapeutischen verwendung
TH31604A (th) อนุพันธ์ของไอโซอินโดล วิธีการเตรียมและการใช้อนุพันธ์ของไอโซอินโดลให้เป็นประโยชน์ในการบำบัดรักษาโรค

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0956855

Country of ref document: EP

REN Ceased due to non-payment of the annual fee